SureTrader SureTrader
Home > Boards > US Listed > Medical - Healthcare > Nxstage Medical, Inc. (NXTM)

7:27AM Nxstage Medical beats by $0.01, beats on

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
surf1944 Member Profile
 
Followed By 415
Posts 22,038
Boards Moderated 2
Alias Born 09/11/06
160x600 placeholder
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/29/2016 5:08:36 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/23/2016 6:08:34 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/22/2016 6:29:05 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/22/2016 6:01:16 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/22/2016 5:57:45 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/21/2016 5:01:36 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/18/2016 5:01:18 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/16/2016 6:50:02 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/16/2016 4:08:25 PM
New Data Shows Better Outcomes, Higher Quality of Life, Lower Cost of Care, and Increased Likelihood for Transplant with More... "PR Newswire (US)" - 11/16/2016 8:00:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 11/14/2016 12:29:50 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 11/4/2016 6:43:13 PM
Quarterly Report (10-q) "Edgar (US Regulatory)" - 11/3/2016 4:36:25 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 11/3/2016 8:20:51 AM
NxStage Reports Third Quarter Financial Results; Raises Full-Year Revenue Guidance And Cuts Net Loss Guidance In Half "PR Newswire (US)" - 11/3/2016 8:01:00 AM
Amended Statement of Ownership (sc 13g/a) "Edgar (US Regulatory)" - 11/3/2016 6:05:23 AM
NxStage Announces Fourth Quarter 2016 Investor Conference Schedule "PR Newswire (US)" - 11/1/2016 8:00:00 AM
NxStage Announces Publication of Journal Supplement with Major Clinical Reviews Supporting More Frequent Hemodialysis Therapy "PR Newswire (US)" - 10/25/2016 8:00:00 AM
NxStage Highlights Innovative Nx2me Platform Data at Partners HealthCare Connected Health Symposium & Expo 2016 "PR Newswire (US)" - 10/21/2016 8:00:00 AM
NxStage® to Report Third Quarter 2016 Financial Results "PR Newswire (US)" - 10/6/2016 8:58:00 AM
Confidential Treatment Order (ct Order) "Edgar (US Regulatory)" - 10/4/2016 10:56:30 AM
NxStage and Satellite Healthcare Announce New Three-Year Home Hemodialysis Agreement that Includes Innovative Nx2me Platform "PR Newswire (US)" - 10/3/2016 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 9/14/2016 5:15:15 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 8/8/2016 4:15:54 PM
NxStage Launches First of Many NxGen Features and Capabilities "PR Newswire (US)" - 8/8/2016 8:00:00 AM
surf1944   Wednesday, 02/29/12 12:11:47 PM
Re: surf1944 post# 6
Post # of 17 
7:27AM Nxstage Medical beats by $0.01, beats on revs; guides Q1 EPS below consensus, revs in-line; guides FY12 EPS, revs below consensus (NXTM) 20.36 : Reports Q4 (Dec) loss of $0.08 per share, $0.01 better than the Capital IQ Consensus Estimate of ($0.09); revenues rose 14.5% year/year to $57 mln vs the $56.25 mln consensus. Co issues guidance for Q1, sees EPS of ($0.09)-(0.11) vs. ($0.06) Capital IQ Consensus Estimate; sees Q1 revs of $56-57 mln vs. $56.94 mln Capital IQ Consensus Estimate. Co issues downside guidance for FY12, sees EPS of ($0.25)-(0.32) vs. ($0.13) Capital IQ Consensus Estimate; sees FY12 revs of $240-245 mln vs. $245.39 mln Capital IQ Consensus Estimate.


surf's up......crikey



SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist